Therapeutic Insights

Found 994 articles

• Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity ConferenceMarch 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s Disease

  3/23/2023

  Vaccinex, Inc. today announced its COO and Senior Vice President, Discovery and Translational Medicine, Elizabeth Evans, PhD, will be making a podium presentation at the AAIC Advancements: Immunity conference.

• Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease

  3/22/2023

  Cognito Therapeutics announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors.

• Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

  3/22/2023

  Alzamend Neuro, Inc. today announced the completion of the clinical portion of its Phase IIA multiple ascending dose (“ MAD ”) study for dementia related to Alzheimer’s.

• Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD™ 2023 Annual Meeting

  3/22/2023

  Eisai Co., Ltd. announced the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta protofibril* antibody for the treatment of Alzheimer's disease, at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders from March 28-April 1 in Gothenburg, Sweden and virtually.

• Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden

  3/22/2023

  Alzheon, Inc. announced that it will be presenting interim findings from an ongoing Phase 2 study evaluating ALZ-801 tablet at the upcoming AD/PD 2023 Conference to be held from March 28 – April 1, 2023 in Gothenburg, Sweden.

• RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer

  3/21/2023

  RayzeBio, Inc. today announced the nomination of a first-in-class novel peptide drug candidate against GPC3. As GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, it has a compelling profile for targeted cancer therapy.

• IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

  3/20/2023

  India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the future.

• Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

  3/18/2023

  Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots of the cystic fibrosis drug Cayston on March 1, 2023, due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

• Nanite Inc. Receives Up to $2M Investment from CF Foundation to Explore a Novel Method to Deliver Genetic Therapies to the Lung

  3/15/2023

  Nanite Inc. announced today an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technology.

• Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting

  3/14/2023

  Prothena Corporation plc announced broad participation at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders being held March 28 – April 1, 2023 in Gothenburg, Sweden, highlighting Prothena's leadership in advancing next generation treatments for Alzheimer’s and Parkinson’s disease.

• ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

  3/13/2023

  ProMIS Neurosciences Inc. today announced an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA.

• ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

  3/13/2023

  ProMIS Neurosciences Inc. today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

• First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis

  3/10/2023

  First Wave BioPharma, Inc. announced that the second patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

• 

  Lilly’s Alzheimer’s Struggles Continue as Preclinical Disease Asset Fails Phase III

  3/9/2023

  Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease.

• SYNAPS Dx Brings El Paso, Texas Marketplace First Highly Accurate Diagnostic Alzheimer’s Disease Test for Patients Diagnosed with Dementia

  3/8/2023

  SYNAPS Dx is pleased to announce that the Advanced Neurology, Epilepsy and Sleep Centers with locations in the El Paso, Texas area will be among the first in the country to offer area residents access to DISCERN™, a minimally invasive diagnostic test.

• Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease

  3/8/2023

  Eli Lilly and Company (NYSE:LLY) announced today that solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease (AD) pathology when initiated in individuals with amyloid plaque but no clinical symptoms of the disease, known as the preclinical stage of AD1.

• ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

  3/8/2023

  Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration Preclinical data that further characterize ongoing programs, including PMN310, to be presented in 2023.

• AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Strategic Partnership to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration

  3/8/2023

  Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced a strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions.

• Advanced Proteome Therapeutics to Proceed with Its Proposed Plan of Arrangement

  3/7/2023

  Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that all conditions have been satisfied or waived and the Board of Directors of the Company has authorized the Company to complete its plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement")

• AlzeCure Participates at Redeye Alzheimer Seminar on March 15

  3/7/2023

  AlzeCure Pharma AB announced that the company is participating at Redeye Alzheimer Seminar on March 15 at 14:10 CET, where CEO Martin Jönsson will present and answer questions about the latest development in the company.